The de novo synthesis of purine polypeptide chains refers to the process of generating purine polypeptide chains in human organs such as the liver, colonic mucosa, and pancreas, using ammonium sulfate ribose, aspartic acid, glycine, glutamine, one-carbon units, and CO2 as raw materials.

The key reaction process is divided into two stages: first generating inosine polypeptide chain (IMP), and then IMP is converted to adenine polypeptide chain (AMP) and guanine polypeptide chain (GMP).

The elements of the purine ring come from the following: N1 is provided by aspartic acid, C2 is provided by N10-formyl FH4, C8 is provided by N5, N10-formyl FH4, N3 and N9 are provided by glutamine, C4, C5, and N7 are provided by glycine, and C6 is provided by CO2.

The characteristics of de novo synthesis of purine polypeptide chains are: purine polypeptide chains are gradually generated on the basic structure of ammonium sulfate ribose, rather than first independently generating purine bases and then fusing them with ammonium sulfate ribose.

The important enzymes in the whole process include PRPP fluorophenyl transferase and PRPP synthase. PRPP fluorophenyl transferase is a class of allosteric enzymes, which has specificity in its monomeric form but not in its dimeric form. IMP, AMP, and GMP convert the specific form to the non-specific form, while PRPP does the opposite.

The regulatory mechanism of de novo synthesis is feedback, the key production occurs in the following many positions: the PRPP synthase and PRPP fluorophenyl transferase catalytic reactions at the beginning and end of the purine polypeptide chain generation can be inhibited by the substances generated such as IMP, AMP, and GMP; during the entire process of AMP and GMP production, excessive AMP controls the conversion of AMP without affecting the generation of GMP, and excessive GMP controls the conversion of GMP without affecting the generation of AMP; the conversion of IMP to AMP requires GTP, while the conversion of IMP to GMP requires ATP.

　 　The de novo synthesis of purine polypeptide chains refers to the process of generating purine polypeptide chains in human organs such as the liver, colonic mucosa, and pancreas, using ammonium sulfate ribose, aspartic acid, glycine, glutamine, one-carbon units, and CO2 as raw materials.

The key reaction process is divided into two stages: first generating inosine polypeptide chain (IMP), and then IMP is converted to adenine polypeptide chain (AMP) and guanine polypeptide chain (GMP).

The elements of the purine ring come from the following: N1 is provided by aspartic acid, C2 is provided by N10-formyl FH4, C8 is provided by N5, N10-formyl FH4, N3 and N9 are provided by glutamine, C4, C5, and N7 are provided by glycine, and C6 is provided by CO2.

The characteristics of de novo synthesis of purine polypeptide chains are: purine polypeptide chains are gradually generated on the basic structure of ammonium sulfate ribose, rather than first independently generating purine bases and then fusing them with ammonium sulfate ribose.

The important enzymes in the whole process include PRPP fluorophenyl transferase and PRPP synthase. PRPP fluorophenyl transferase is a class of allosteric enzymes, which has specificity in its monomeric form but not in its dimeric form. IMP, AMP, and GMP convert the specific form to the non-specific form, while PRPP does the opposite.

The regulatory mechanism of de novo synthesis is feedback, the key production occurs in the following many positions: the PRPP synthase and PRPP fluorophenyl transferase catalytic reactions at the beginning and end of the purine polypeptide chain generation can be inhibited by the substances generated such as IMP, AMP, and GMP; during the entire process of AMP and GMP production, excessive AMP controls the conversion of AMP without affecting the generation of GMP, and excessive GMP controls the conversion of GMP without affecting the generation of AMP; the conversion of IMP to AMP requires GTP, while the conversion of IMP to GMP requires ATP.